Inclusion Criteria:~* Adults 55-90 years at the time of signing consent~* A diagnosis of probable Alzheimer
disease (AD), defined by the National Institute of Neurological and Communicative Disorders and Stroke and the
Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria~* Previous computed tomography or
magnetic resonance imaging scan of the brain with findings consistent with a diagnosis of Alzheimer disease~* A
diagnosis of behavioral symptoms that include any of the following: delusions, hallucinations,
agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition,
irritability/lability, aberrant motor behavior, sleep and nighttime behavior disorders and appetite and eating
disorders~* Onset of behavioral symptoms at least 4 weeks prior to screening.~* Treatment with antipsychotic
medication for at least 4 weeks prior to the hMSC infusion.~* Patients unable to consent should have a Legally
Authorized Representative or Proxy to provide consent on their behalf.~* Have a family member or friend (study
partner) who has frequent and sufficient contact with the patient and able to answer questions about the
participant's behavior.~
